🔗 Share this article

As the United States undertakes unprecedented revisions to its vaccine recommendations, a particular individual appears unexpectedly: Tracy Beth Høeg, a Danish American sports physician and epidemiologist who rose to prominence by questioning COVID-19 shots in the global health crisis and has zeroed in on possible deaths following Covid vaccination in her brief tenure at the Food and Drug Administration.

Scheduled Overhauls to Pediatric Immunization Schedule

Agency leaders had intended to unveil major revisions to the pediatric immunization program earlier this month, synchronizing the US with Denmark’s national calendar, according to reports – a substantial departure that would put the US out of step with much of the world with insufficient data for improved outcomes. The planned update has been postponed until the next year.

In place of the director of the vaccine center, Tracy Beth Høeg is set to address the audience at the gathering. She was newly appointed acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the office this year.

A Shift at the Regulatory Body

This interim role could signify a tighter collaboration between the drug and vaccine branches as Høeg and Prasad consolidate power at the FDA – and it signals a greater focus upon reevaluating previously authorized vaccines at the FDA.

Dr. Høeg has frequently advocated for discontinuing certain pediatric vaccine recommendations in the US so as to align more in line with the Danish model, a country with universal health coverage and a number of inhabitants about the size of Wisconsin’s.

To date comments, she has kept her attention on vaccines – traditionally the domain of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than medication approval.

Concerns Over Background

Dr. Høeg has no obvious experience in drug development, approval processes or leadership, which has been customary for past leaders of the Center for Biologics Evaluation and Research. She has served at the FDA as a top consultant to the agency head and the vaccine center since March.

“It seems she lacks to have any of the qualifications” for overseeing the pharmaceutical oversight division, remarked Jonathan Howard. “She lacks experience running a clinical trial. She has no expertise in managing a large organization. She lacks background in industry regulation.”

Previous heads of CBER would “grasp legal statutes and the research of pharmaceutical innovation”, said Dr. Janet Woodcock. “Clearly, she doesn’t have the type of experience that former directors who headed the center have had.”

This division has an vast range of responsibilities at the FDA, she emphasized.

“The public just zeroes in on the innovative therapies, but the generic drug division authorizes thousands of off-brand pharmaceuticals. There’s a biosimilars division, non-prescription drug unit and other areas, and every single one have to be supervised,” she explained. “The area you overlook, that’s the thing that I always told people is going to cause problems.”

There is also, a substantial administrative aspect to the role, which manages over 5,000 employees. “It’s a enormous leadership role, if you execute it properly,” Woodcock said.

Agency Reaction and Controversial Initiatives

When asked about concerns about Høeg’s qualifications and whether this appointment represents more teamwork among regulatory chiefs on immunizations, a spokesperson said that the “inquiries rely on inaccurate premises”.

“This background is consistent with the responsibilities of her position,” the official said, noting the months Høeg spent guiding the agency head on “pharmaceutical safety and regulatory science, including computational safety modeling and shot safety tracking”.

As acting director, Høeg assumes responsibility for the commissioner’s new fast-track approval initiative, a controversial one-day drug-approval program that apparently concerned her predecessors. “How are these drugs being chosen for this fast-track system? Who takes the calls?” Dr. Howard questioned. “There’s a lot of confidentiality occurring at the agency right now.”

Broadly speaking, he stated, “the agency looks to be trending towards less stringent rules of most medications, except for immunizations.”

Documented History on Vaccines

With immunizations, Høeg has a clearer, if troubling, past, Howard have noted. She published a research paper using unverified volunteer-provided data to estimate the rate of myocarditis after COVID-19 vaccination. She advised the Florida top health official Dr. Joseph Ladapo, who allegedly have changed statistics to imply Covid vaccinations are more dangerous than they are.

Part of her “policy goals” for the incoming government encompassed revising rules for novel immunizations and halting “non-essential” vaccines, she remarked following the vote on a online show. At the agency, Høeg has reportedly proposed barring adolescent males from obtaining Covid vaccinations.

“She is an complete ideologue who begins with her preconceived notions and reverse-engineers to fit the data in a extremely disingenuous, dishonest fashion,” Howard argued.

Consolidating Power and a “Push for Payback”

Høeg aligned with other dissenters, {like|